From studying DNA in the lab to working with patients in clinical trials, Amgen scientists are pioneering new approaches to understanding human biology and making innovative medicines to treat disease. Join leaders at Amgen and beyond for in-depth discussions of the latest science and discoveries in our podcasts developed in collaboration with The Scientist.
Out Now: Human Data Era
By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition.
In the Human Data Era podcast, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.
Launched Oct 20, 2022
Human Data: Beyond the Genome
with Rob Lenz, M.D., Ph.D., senior vice president of Global Development at Amgen
New Connections Between Genetics and Human Disease
with Nancy Cox, Ph.D., director of the Vanderbilt Genetics Institute
Exploring Human Data in Cardiovascular Disease
with Narimon Honarpour, M.D., vice president of General Medicine, Global Clinical Development at Amgen
The Role of Human Diversity in Progressing Precision Medicine
with Kári Stefánsson, M.D., founder, deCODE Genetics
Innovating Clinical Trials
Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress.
In this four-part series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop potential new medicines that benefit patients.
Launched Sept 1, 2022
with Dr. Cynthia Verst, President, Design and Delivery Innovation, R&D Solutions at IQVIA
Real World Data in Drug Development
with Brian D. Bradbury, D.Sc., Vice President, Center for Observational Research at Amgen
The Right Patients
with Dr. Ponda Motsepe-Ditshego, Vice President and Therapeutic Area Head of Global Medical, General Medicine at Amgen
Real-World Clinical Trial Design and Execution in Oncology
with David Raben, M.D., Vice President Global Development & Product General Manager, Oncology at Amgen
The Generative Biology Revolution
Generative biology is a revolutionary approach to drug discovery and development that leverages AI and machine learning to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of drug discovery.
In this four-part series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.
Launched June 23, 2022
The Cresting Wave of Transformational Science
with Alan Russell, Ph.D., vice president of Biologics
The Protein Structure Prediction Problem
with Mike Nohaile, Ph.D., Chief Scientific Officer, Generate Biomedicines
with David Baker, Ph.D., Institute for Protein Design, University of Washington
Accelerating Drug Discovery
with Suzanne Edavettal, Ph.D., executive director of Protein Engineering
In this five-part series, Ray Deshaies hosts conversations with leading scientists to take a deep dive into the most promising new ways to treat disease as we enter a fourth wave of innovation. Listen in to learn how the current wave of discovery, led by new types of multispecific medicines, has the potential to radically alter our concept of how drugs can work and pave the way for new solutions.
The Next Wave of Drug Development
with Ryan Potts, Ph.D., executive director, Research and head of Induced Proximity Platform at Amgen
The Biology of PROTACs
with Craig Crews, Ph.D., professor of Molecular, Cellular and Developmental Biology, Yale
Discovery at the DNA Encoded Library
with Alex Gouliaev, Ph.D., vice president, Amgen Research Copenhagen
The emerging IPP toolkit
with Carolyn Bertozzi, Ph.D., professor of Chemistry, Stanford
Induced Proximity: Reason for Optimism in Treating Cancer and Beyond
with David Reese, M.D., executive vice president, Research and Development, Amgen
DNA Unlocked, a 5-part podcast series about the twists and turns, highs and lows of the quest to generate insights from DNA sequencing that will solve some of the most challenging questions in the biology of disease.
Join host Ray Deshaies to go deep on how scientists are approaching the mountains of genomic data to tackle longstanding barriers to drug discovery, unlock cancer, and learn first-hand about exciting ideas 'coming around the bend.'
Reshaping the Future
with Amit V. Khera, M.D., MGH Center for Genomic Medicine
Unlocking the Genetics of Cancer
with Angela Coxon, Ph.D., vice president of Oncology Research at Amgen
with Larry Gold, Ph.D., founder of Somalogic
Genetics vs. Biology
with Saptarsi Haldar, M.D., vice president of Cardiometabolic Research at Amgen
Promise and the Potential
with Richard Scheller, Ph.D., former chief scientific officer of 23andMe and former executive vice president of Research and Early Development at Genentech